Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Pharma company presents broad antiviral potential of Tarvacin at conference
July 24th, 2005
Peregrine Pharmaceuticals, Inc., (PPHM) presented new data at the Biotechnology Industry Organization 2005 (BIO 2005) annual meeting in Philadelphia, Pennsylvania, supporting the broad antiviral potential of Tarvacin. The data presented at BIO 2005 showed that Tarvacin binds to enveloped virus particles representing 6 different virus families, binds to virally infected cells and inhibits viral replication in multiple virus systems. The data also indicated that Tarvacin provided significant protection against Cytomegalovirus (CMV) and Pichinde virus (an in vivo Lassa fever model) infections. Data presented at the conference demonstrated: ...
Source: Medical Letter on the CDC & FDA (2005-07-24)
|
